A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted results- Registry ID
- NCT06958536
- Phase
- Phase 2
- Recruitment
- Enrolling participants
- Sponsor
- Sanofi
- Design
- Randomized
- Comparator
- Brivekimig Dose Regimen A; Brivekimig Dose Regimen B; Placebo
- Planned enrollment
- 99
- Endpoint
- Percentage of participants who achieve endoscopic response at Week 16
Study ages: 18 Years to 75 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Australia, Belgium, China, Czechia, France, Germany, Japan, Poland, South Africa, Spain, United Kingdom, United States.
Sites marked recruiting: Australia, Belgium, China, Czechia, France, Germany, Japan, Poland, South Africa, Spain, United Kingdom, United States. Check the original registry record for locations and study-team contacts; overall recruiting status does not guarantee a local place.
Primary data collection: Dec 17, 2026 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1